News | Radiation Therapy | September 19, 2017

Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting

Automated processes and actionable analytics help enhance patient care, increase productivity and reduce costs through easy-to-use operational dashboards and visual reports

Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting

September 19, 2017 — Elekta will highlight its Mosaiq Oncology Analytics (MOA) software solution at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 24-27 in San Diego. MOA maximizes an electronic health record’s (EHR’s) potential to ensure clinics run at peak efficiency. MOA works seamlessly with single and multiple Mosaiq oncology information systems, either with Elekta Cloud Solutions or on premises, providing the actionable practice information needed to quickly assess and adapt to issues affecting quality of care, productivity and cost.

Elekta works with customers to tailor and validate the MOA dashboard to their specific needs, according to Andrew Wilson, vice president of global marketing for software solutions. Each MOA package is implemented so that it automatically pulls all the data that a specific client requires.

Other key benefits of MOSAIQ Oncology Analytics include:

  • Critical actionable information to help improve care for cancer patients, ensuring timely access to treatment by reducing wait times, eliminating bottlenecks and improving workflows; and
  • Efficient analysis of treatment patterns based on a variety of diagnostic indicators. These analyses readily identify trends and best practices that have the potential to improve patient outcomes. Periodic reviews of planned treatment doses, treatment plan variations, toxicity and survival help to enhance treatment efficacy.

ASTRO attendees are invited to visit Elekta to learn more about other new innovations and advanced technologies, including:

  • Magnetic resonance/radiation therapy (MR/RT), a new approach to radiation therapy in which magnetic resonance imaging (MRI) images are captured either prior to or during the fraction being delivered. Visualization of tumor position, shape, biology and surrounding tissue during radiation delivery may enable targeted adaption of the cancer treatment in real time, enabling critical advances in safety and efficacy. New technology will be presented that provides clinicians the ability to ‘see while you treat’ that may enable reductions in treatment margins around the tumor and thereby spare more healthy tissue. It may also allow clinicians to deliver a higher dose of radiation per fraction to the tumor, which may improve cancer treatment regimens and the efficiency of delivering radiation oncology care;
  • Leksell Gamma Knife Icon, which offers high-definition (HD) motion management and stereotactic cone beam computed tomography (CBCT) imaging allowing for precision intracranial radiosurgery with online dose adaptation, while also supporting instantaneous clinical decision-making and flexibility for frame-based and frameless immobilization;
  • High-definition dynamic radiosurgery (HDRS), a capability leveraging the core strengths of Versa HD linear accelerator and Monaco treatment planning system. Versa HD combines HDRS treatment capabilities and precision radiotherapy in a single platform, offering precision and speed to deliver stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments throughout the body in standard treatment time slots. Monaco powers more efficient high-definition planning with true Monte Carlo accuracy and advanced multi-criterial optimization; and
  • Elekta’s image-guided adaptive brachytherapy applicators and unified treatment planning and delivery platforms. This includes Venezia, a new gynecologic brachytherapy applicator designed to treat advanced cervical cancer, including disease with extra-cervical spread such as the parametrium and vagina.

For more information: www.elekta.com

Related Content

Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
NVIDIA Explores Role of AI, Analytics and Virtualization in Healthcare at HIMSS19
News | Artificial Intelligence | February 13, 2019
Digital technology company NVIDIA will highlight its newest partnerships to advance the digital transformation of...
Hologic Launches Unifi Analytics Business Intelligence Tool
Technology | Analytics Software | February 12, 2019
Hologic Inc. announced the U.S. launch of Unifi Analytics, a business intelligence tool that allows healthcare...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes

Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes. The metallic-based nanoparticles show up on CT scans so it can be used as a permanent fiduciary marker to track tumor response. The images show the initial tumor and enhancement areas due to the nanoparticles and the resulting outcomes following treatment. Photo by Dave Fornell

Feature | Radiation Oncology | January 30, 2019 | By Dave Fornell
Artificial intelligence (AI) has been the hot topic discussed at all trade shows, and the...